• Users Online: 60
  • Print this page
  • Email this page
Year : 2018  |  Volume : 15  |  Issue : 3  |  Page : 132-134

Novel drug - dinutuximab for high-risk neuroblastoma

1 Department of Paediatrics, Yenepoya Medical College and University, Mangalore, Karnataka, India
2 Department of Anaesthesia, Kasturba Medical College, Mangalore, Karnataka, India
3 Department of Pediatrics, Yenepoya Medical College, Mangalore, Karnataka, India

Correspondence Address:
Supriya Kushwah
Department of Paediatrics, Yenepoya Medical College and University, Deralakatte, Mangalore, Karnataka
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/am.am_14_17

Rights and Permissions

Neuroblastoma is the most common extracranial tumor in children aged <5 years. Prognosis of high-risk neuroblastoma is not good even after use of aggressive chemotherapy. Newer drug anti-GD2 monoclonal antibodies, dinutuximab in combination with granulocyte-macrophage colony-stimulating factor or interleukin-2, have been recently approved by Food and Drug Administration for the treatment of high-risk neuroblastoma. Dinutuximab binds to the glycolipid GD2 present on neuroblastoma cells and cells of neuroectodermal origin and enhances cell lysis through antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded96    
    Comments [Add]    

Recommend this journal